TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07023835: Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Sponsor: Zydus Therapeutics Inc. · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 240 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,965,500

Rescue Site Savings

+$2,626,500

Unlock Full NCT07023835 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07023835 Rescue Dossier →